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Colorectal primary signet ring cell carcinoma (PSRCCR) is a rare entity with a dismal
prognosis,mainlybecauseofdelayeddiagnosis.Theobjectiveofthisstudywastoinvestigate
the clinicopathologic features and prognostic factors for PSRCCR. This is a retrospective
study including the data of 22 patientswith PSRCCRwhounderwent surgery. Patientswere
categorized by age, sex, tumor site, and stage. Fifteen patientsweremale.Median agewas 40
years. Sites for metastases were lymph nodes (86.4%), peritoneum (40.9%), and liver (9.1%).
Most of the patients (91%) had stage III or IV tumors. The rates of curative and palliative
resections performedwere equal.Mean overall survival andmeanprogression-free survival
timeswere foundtobe33.36 7.1months (95%confidence interval, 19.4–47.2months)and11.8
6 3.5 months (95% confidence interval, 4.9–18.7months), respectively. It was concluded that
site of the tumor, presence of bowel obstruction, peritoneum and lung metastases, adjacent
organ infiltration, TNM stage, and efficiency of surgery have significant effects on survival.
All inall, these aggressive tumors are generallydiagnosedat advanced stages.Dependingon
the situation, survival is shorter. A high degree of vigilance is required for these patients to
avoid the negative impact of late diagnosis on survival.
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Primary signet ring cell carcinoma is a tumormost commonly located in the stomach, and
less frequently in the breast, gallbladder, bladder, and
pancreas.1 Primary signet ring cell carcinoma of the
colon and rectum (PSRCCR) is a rare entity, with a
reported incidence of less than 1%.2 It has a markedly
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poor prognosis.3 Because symptoms often develop
late, it is usually diagnosed at an advanced stage.4
Furthermore, it typically appears in young adults.5
Macroscopically, PSRCCR shows the characteris-
tic appearance of linitis plastica, as a shrunken, rigid
structure.1–5 Histologically, the neoplastic cells re-
semble signet rings because they contain abundant
intracytoplasmic mucin, which pushes the nuclei to
the periphery.1–5 The presence of mucus secretion in
microscopic examinations of the tumor is one of the
most important parameters determining the biologic
behavior of colorectal carcinomas; other factors are
age, sex, tumor location, tumor diameter, grade,
stage, lymphatic and vascular invasion, periserosal
overgrowth, and distant metastasis.6,7
So far, only a limited number of case reports have
been published on this subject. Most publications
have reported on a small number of patients and
have presented controversial results. The objective
of this study was to investigate the characteristic
clinicopathologic features of colorectal signet ring
cell carcinomas and the parameters affecting prog-
nosis within our patient group.
Patients and Methods
Data collection
The study was conducted according to the recom-
mendations of the Declaration of Helsinki on
Biomedical Research involving Human Subjects. This
retrospective clinical study was performed in the
Baskent University Department of General Surgery
after obtaining the approval of the university ethics
committee (KA08/188). In November 2006, a colo-
rectal cancer database was set up containing clinico-
pathologic information for each patient and
corresponding data. Eligible cases were selected from
this database. From March 2007 to June 2013 a total of
842 cases of primary colorectal cancer were diag-
nosed and treated at our centers. Signet cell
carcinoma of the colon or rectum was observed in
22 of these patients. The pathologic diagnosis was
made by specially trained pathologists, and curative
resection was the preferred approach for treating
colorectal cancers when possible. Curative surgery
was defined as radical resection including lymphatic
dissection with surgically clean margins upon micro-
scopic examinations.
Patient demographics and tumor characteristics
Demographic records for each patient included age,
sex, and family history of malignancy, as well as
presence of bowel obstruction, surgical treatment,
tumor presence at surgical margins, recurrence, and
mortality. Cancer-specific information included tu-
mor location, size, grade and depth of infiltration,
and the presence of metastatic lymph nodes,
adjacent organ invasion, hepatic metastasis, and
peritoneal dissemination.
In accordance with the definition of the World
Health Organization, signet ring cell carcinoma is
diagnosed when a colorectal tumor contains at least
50% signet ring cells.8 In addition, tumors were
staged according to the new (American Joint
Committee on Cancer 7th edition) TNM classifica-
tion.9 Complete pathologic staging was available
only in patients after tumor resection.
Survival and statistical analysis
Follow-up controls were routinely scheduled at 3-
month intervals for the first 2 years, every 6 months
for the subsequent 3 years, and annually thereafter.
Data were collected and analyzed digitally using the
SPSS version 17.0 (Statistical Software for Social
Sciences Inc, Chicago, Illinois) program for statistics.
Cumulative event rates were calculated using the
Kaplan-Meier method, and survival curves were
compared using the log-rank (Mantel-Cox) test.
Adjusted hazard ratios and 95% confidence inter-
vals (95% CIs) were used for estimation. The 12
factors thought to influence mortality are age (40
years or .40 years), sex, family history of malig-
nancy, site of primary tumor (right hemicolon, left
hemicolon, and rectum), presence of bowel obstruc-
tion, tumor size (5 cm; .5 cm to 10 cm; .10 cm),
stage of the tumor, site of distant metastasis
(peritoneum, lung, and liver), depth of invasion,
presence of adjacent organ infiltration, surgical
treatment type, and presence of additional thera-
pies. Overall survival was determined as time
interval between histologic diagnosis and death or
the last follow-up. In addition, progression-free
survival time was calculated from the date of
histologic diagnosis until tumor progression or
death. The results of both the overall survival and
the progression-free survival times are presented as
mean values for their continuous variables. For all
tests, P , 0.05 was considered to be statistically
significant.
Results
Of the 842 patients with primary colorectal cancers
who underwent surgery, 2.6% (n ¼ 22) presented
BELLI SIGNET RING CELL CARCINOMA OF COLORECTUM
692 Int Surg 2014;99
with histologically verified signet ring cell carcino-
mas (Figs. 1 and 2). Only one of these patients
exhibited a synchronous primary malignant disease
(gastric cancer). This gastric cancer, which was
determined during preoperative examinations by
chance, was an early-stage adenocarcinoma
(T1N0M0). As for signet ring cell colon cancer, it
was at stage IIIC. Because of its detection at an early
stage and because the patient received curative
treatment, this gastric cancer is thought not to have
an effect on prognosis. Because colon cancer was
considered to determine the survival, this patient
was included in the study. The demographics and
perioperative clinicopathologic features of these 22
PSRCCR patients are detailed in Table 1. Many of
these patients (54.5%; n ¼ 12) with signet ring cell
carcinoma were younger than 40 years at the time of
the diagnosis. In addition, 59% of the signet ring cell
carcinomas (n¼ 13) were located in the rectum. The
sites of the primary tumors are detailed in Table 1.
A curative resection (R0 resection with related
radical lymphatic dissection) was achieved in 11 of
the 22 patients (50%). Palliative resections were
performed on the remaining 11 patients. The mean
survival time was calculated as 48.4 6 10.8 months
(95% CI, 27.2–69.5 months) for the patients who
underwent curative resection and 19.2 6 7.3 months
(95% CI, 4.9–33.4 months) for those who underwent
palliative resection. Emergency procedures had to
be performed in 54.5% of patients (n ¼ 12) with
PSRCCR because of signs of bowel obstruction.
Diverting colostomy or ileostomy was applied for 14
patients (63.6%). As for the risk of metastasis and
local invasion according to preoperative examina-
tions (magnetic resonance imaging and/or comput-
ed tomography), neoadjuvant radiochemotherapy
was applied for 5 patients. A total of 18 patients
were exposed to postoperative adjuvant therapies.
The applications of adjuvant and neoadjuvant
therapies are shown in Table 1.
The tumor stage according to TNM classification
is presented in Table 1. There was a tendency
toward advanced tumor stage at the time of
presentation (91%; n¼ 20; stages III and IV). A total
of 10 of the 22 patients (45.5%) with signet ring cell
carcinomas presented with distant metastasis at the
time of diagnosis. The most common site for
metastases was peritoneum in 9 patients (40.9%);
less common was lung in 3 patients (13.6%) and
liver in 2 patients (9.1%). In addition, the depth of
invasion was T3 or T4 in 18 of the 22 patients
Fig. 1 Two cases in which the signet
ring cells have invaded the mucosa of
the (a) left colon and (b) rectum, as seen
in these 2 different colon specimens
(hematoxylin and eosin, 3100).
Fig. 2 Using endoscopic biopsy prior to surgery, the signet ring
cells can clearly be seen to have invaded the rectal mucosa
(hematoxylin and eosin,3100).
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(81.8%). In addition to this, tumor invasion of the
lymphatic vessels occurred in 19 patients (86.4%).
None of the patients had inflammatory bowel
disease.
The mean survival time observed for the entire
group of patients with signet ring cell carcinoma
was 25.9 6 25.6 months (range, 1–81 months), and
the mean overall survival was found to be 33.3 6 7.1
months (95% CI, 19.4–47.2 months; Fig. 3A).
There was a statistically significant difference for
the survival rates between the group that under-
went emergency surgery (bowel obstruction) and
patients who underwent elective surgery; the rate of
those who underwent emergency surgery was 20.1
6 6.6 months (95% CI, 7.1–33.1 months) compared
with an average rate of 48.2 6 10.2 months (95 CI%,
28.2–68.2 months) for those who underwent elective
surgery (P¼ 0.043). Similarly, it was determined that
the site of the primary tumor (right hemicolon, left
hemicolon, and rectum), TNM stage, adjacent organ
infiltration, peritoneum, and lung metastasis status,
as well as efficacy of surgery (palliative or curative),
all showed statistically significant difference (P ,
0.05; Table 1) in terms of survival. Right colon and
rectum tumors had a worse prognosis compared
with left colon tumors [left colon, 25.8 6 13.2
Table 1 Analysis of factors that may affect mortality/survival
Variable Patients N (%) or mean 6 SD (range)
Log-rank (Mantel-Cox)
v2 P value
Age, y, median 6 SD (range) 40 6 16 (21–76) 0.291 0.590
No. (%) of patients age 40 y 12 (54.5)
No. (%) of patients age .40 y 10 (45.5)
Sex, No. (%) 0.0001 0.985
Male 15 (68.2)
Female 7 (31.8)
Family history, No. (%) 1.576 0.209
Present 5 (22.7)
Absent 17 (77.3)
Site of primary tumor, No. (%)a 9.543 0.023
Right hemicolon 3 (13.6)
Left hemicolon 6 (27.3)
Rectum 13 (59.1)
Obstruction of the bowel, No. (%)a 4.089 0.043
Present 12 (54.5)
Absent 10 (45.5)
Tumor diameter (5 cm, .5 to 10 cm, .10 cm), mean 6 SD (range) 7 6 3.6 (3–16) 3.396 0.183
TNM staging, No. (%)a 13.591 0.004
I 1 (4.5)
II 1 (4.5)
IIIC 10 (45.5)
IV 10 (45.5)
Site of distant metastasis, No. (%)b
Peritoneuma 9 (40.9) 6.040 0.014
Lunga 3 (13.6) 5.152 0.023
Liver 2 (9.1) 2.521 0.112
Depth of invasion, No. (%) 1.726 0.189
T1/T2 4 (18.2)
T3/T4 18 (81.8)
Organ infiltration, No. (%)a 9.108 0.003
Present 13 (59.1)
Absent 9 (40.9)
Surgical treatment, No. (%)a 6.675 0.010
Curative 11 (50)
Palliation 11 (50)
Additional therapies
Neoadjuvant radiochemotherapy 5/22 (22.7) 0.593 0.441
Adjuvant radiochemotherapy 18/22 (81.8) 1.001 0.317
aStatistically significant factors (P , 0.05).
bMetastases were found in 1 patient on 3 different sites and in 2 patients on 2 different sites.
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months (95% CI, 0–51.6 months); right colon, 27.2 6
10.7 months (95% CI, 6.3–48.2 months); and rectum
36.8 6 9.7 months (95% CI, 17.7–56 months); Fig.
3B]. High TNM stage with the presence of adjacent
organ infiltration, along with peritoneum and lung
metastasis, correlated with an unfavorable progno-
sis. The patients for whom curative surgical treat-
ment was performed were more likely to have a
favorable prognosis than those who underwent
palliative treatment.
It was found that age (40 years or .40 years),
sex, family history, the size of the tumor, presence of
liver metastasis, depth of invasion, and addition of
adjuvant as well as neoadjuvant therapies, had no
statistically significant effect on the survival period
(P . 0.05).
The mean survival time was calculated as 52.7 6
11 months (95% CI, 31.2–74.2 months) in patients
who underwent R0 resection and 18 6 6.7 months
(95% CI, 4.8–31.2 months) in the others (Fig. 3C). Of
these 22 patients, 15 died during the follow-up
period. Of these 15 patients, 10 had stage IV disease
(all of the patients with stage IV disease) and 5
patients had stage IIIC disease. The mean progres-
sion-free survival time of these patients was 11.8 6
3.5 months (95% CI, 4.9–18.7 months).
Discussion
PSRCCR is a rare type of colorectal cancer that
accounts for 0.1% to 2.6% of all colorectal cancer
cases.10 This rate rises to 19% in different series.6 In
an analysis of PubMed articles, when ‘‘signet ring
cell carcinoma,’’ ‘‘colon,’’ and ‘‘Turkey’’ are used as
key words in the investigation of related literature,
there are 6 articles, most of which are case reports.
No information about the rate of PSRCCR is
available. In our series, patients who underwent
an operation for PSRCCR accounted for 2.6% of all
primary colorectal cancers. This percentage is close
to the upper value mentioned in the literature. This
relatively high frequency may be due to the
specialties and experience of our pathologists and
close sections obtained from specimens in order to
not overlook disease.
It is emphasized in this study that PSRCCR is an
aggressive tumor that is commonly seen around the
age 40 years and generally has a poor prognosis. In a
study where signet ring cell adenocarcinoma of the
rectum was compared with non–signet ring cell
mucinous adenocarcinoma of the rectum in addition
to nonmucinous adenocarcinoma of the rectum. The
mean age of patients at onset with signet ring cell
adenocarcinoma was 48.1 years while it was 57.4
years for patients with non–signet ring cell mucin-
ous adenocarcinoma of the rectum and 62.6 years
for nonmucinous adenocarcinoma of the rectum.11 It
was suggested in the same study that PSRCCR had
male predominancy, with a ratio of 67.2%.11,12
Concordant with our data, in data presented by
Bittorf et al,12 patients who underwent operations
Fig. 3 Kaplan-Meier overall survival curve (A); survival analysis
according to the location of the tumor (B); and survival analysis of
the patients who could or could not have R0 resection performed
upon them (C).
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for signet ring cell carcinoma were younger at the
time of diagnosis, with a median age of 40. Similar
to previous publications, we observed a male
predominance (68.2%) for PSRCCR patients.10,13,14
Parallel with the previous studies, in the current
study age and sex were shown not to have any
significant effect on survival.12,15,16 As opposed to a
study suggesting that female sex had a worse effect
on survival, it was found in the current study that
there were no differences in survival between sexes.
Although there are various data concerning the size
of tumors in the literature, it was suggested that
well- and moderately-differentiated carcinomas
might be diagnosed at larger sizes (5.5–6.2
cm).6,7,11 However, in our study the tumors were
even larger, with a mean diameter of 7 cm. As our
center is commonly considered to be a referral
hospital, many problematic patients are admitted to
our hospital. Thus, the diameters of the tumors
might be larger than those mentioned in literature at
the time of diagnosis. In a study it was suggested
that there were no effects of the size of the tumor on
survival15; in a similar fashion, we obtained an
identical result.
Most publications suggest that in these cases it is
found that the right colon and rectum are the most
frequent sites for PSRCCR.7,17 In a study performed
in Japan, it was suggested that signet ring cell
carcinoma of colon clearly existed in a proximal
location.15 On the contrary, in our study rectum was
found to be prominent, with 59%, and the left colon
after it, with 27.3%. Recently, it has been found that
there has been an increase in the ratio of tumors in
the right colon and a decrease in the left for well-
and moderately-differentiated carcinomas.18 On the
contrary, PSRCCR tumors, which have aggressive
characteristics, were shown to be more evident in
rectum and left hemicolon in our series.
In the survival analysis, it was confirmed that
tumor site had a significant effect on survival. In this
study, rectal tumors were detected to have the best
prognosis according to tumor site. As opposed to
our results, in a previous study in which PSRCCR
tumors were divided into two groups according to
their localization, proximal tumors had a better
prognosis.15
Hereditary nonpolyposis colorectal cancers usu-
ally develop in the right colon. However, signet ring
cell carcinomas can also develop in the right colon
and should not be underestimated. Hereditary
nonpolyposis colorectal cancer generally presents
with mucinous carcinoma in young patients.19 In
our series, 1 patient had colon cancer related to
hereditary nonpolyposis colorectal cancer, which
was located in the right colon.
Patients with ulcerative colitis have an increased
long-term risk for developing signet ring cell
carcinomas and mucinous carcinomas compared
with the general population.2,7 In contrast, in our
series no patients were observed to have ulcerative
colitis.
In a study in which patients with the diagnosis of
signet ring cell carcinoma of the rectum were
examined, according to the TNM classification 10%
were at stages I and II, 30% were at stage III, and
41% were at stage IV.11 In another study, in which
154 patients were studied, 78.2% of patients were
identified as having stage III or IV disease. In
addition, in this study lymph node involvement was
determined in 77.4% of patients, peritoneal metas-
tasis in 38.7%, and liver metastasis in 2.9%.17 In our
study the rates were 9% for stages I to II, 45.5% for
stage III, and 45.5% for stage IV. In line with the
former publications, we diagnosed most signet ring
cell cancers at advanced stages.7,11–17 Data pub-
lished concerning lymphatic and vascular invasions
are generally heterogeneous. In accordance with
Tung et al13 and Makino et al,17 in our series
metastasis tended to develop in lymph nodes and
on peritoneal surfaces rather than in the liver. In a
study in which carcinoma metastases were exam-
ined, it was reported that the rate for peritoneum
metastases was 38%, and the rate for metastases that
spread out to other sites (including liver, lung, brain,
and bone metastases) through hematogenous route
was 18.5%.11 In other studies, 92.8% of the patients
with a PSRCCR diagnosis were at stages III and IV,
64.3% of them had peritoneum metastases, and
14.3% of them had liver metastases7 Parallel with
those rates, 81.8% of our patients had T3 to T4
tumor, 40.9% had peritoneum metastases, 13.6% had
lung metastases, and 9.1% had liver metastases. It
was determined that 91% of our patients were at
stages III and IV. In the survival analysis, TNM stage
and presence of peritoneum and lung metastases, as
well as adjacent organ infiltration, had significant
effects on prognosis. However, it was found that
depth of invasion and presence of liver metastasis
had no effects on survival. In the studies performed
it was reported that TNM stage had a significant
effect on survival.11 Accordingly, there were no
relevant studies available performed on the param-
eters mentioned above.
PSRCCR is the result of a tumor with diffuse
infiltration of the intestines and a circular thickening
of the bowel wall, and thus it can be recognized as
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the solidification is established; therefore, it is called
‘‘colonic linitis plastica.’’ However, larger tumors
with mass effect were observed in our series. This
phenomenon may be due to the arrival of the cases
at relatively later stages. It should be considered that
PSRCCRs at advanced stages may form more
vegetating and large masses.
Curative resection was achieved with the appro-
priate surgical approach in half of the patients in
our study. This rate was lower in different
studies.7,17 This can be explained by the advanced
stage of the tumor at the time of diagnosis and the
underlying biologic behavior. Most published
studies argue that it is difficult to diagnose this
histologic type of cancer with a small amount of
tissue obtained by an endoscopic biopsy done
before surgery. However, 4 of the patients in our
study group were given the correct diagnosis by
using endoscopic biopsy prior to surgery (Fig. 2).
Because endoscopic biopsy samples represented
limited pieces of tumors, final results were report-
ed by their definitive diagnoses (e.g., malignant
tumor containing signet ring cells). To be defined as
PSRCC, demonstration of more than 50% signet
ring cells is recommended.
It was found in the survival analysis that the
presence of bowel obstruction and having only
undergone palliative surgery were correlated with
a worse prognosis. However, additional therapies
(neoadjuvant radiochemotherapy and adjuvant
radiochemotherapy) had no effects according to
survival analysis. It seems that there are no studies
related to PSRCCR that examine the effect of bowel
obstruction and palliative surgical treatment on
survival. On the other hand, there are various
studies claiming that the presence of bowel
obstruction and palliative surgical treatment in
patients with well- and moderately-differentiated
colorectal carcinomas had negative effects on
survival.20
PSRCCR generally has a poor prognosis. A
relatively high proportion of these cases receive a
delayed diagnosis, leading to advanced tumor stage
and shortened lifespan. Survival rates over a 5-year
period in previous studies ranged between 9% and
36%.10–17,21 Average survival time was reported to
be between 20 and 45 months.4,17,21 Similar to the
results in our study, the mean overall survival and
mean progression-free survival times were found to
be 33.3 6 7.1 months (95% CI, 19.4–57.2 months)
and 11.8 6 3.5 months (95% CI, 4.9–18.7 months),
respectively.
Conclusion
Overall, we demonstrated that PSRCCR was mostly
seen in the early fifth decade of life, with male
predominance, in rectum. Furthermore, it can also
be concluded that survival rates were influenced by
the site of the tumor, the presence of bowel
obstruction as well as peritoneum and lung metas-
tases, the TNM stage, and the efficiency of the
surgery implemented. However, tumor size, liver
metastasis, depth of invasion, and additional ther-
apies seem to have no significant impact on
survival. In general, the prognosis for patients with
PSRCCR is extremely poor; this can only be
recovered by early diagnosis and aggressive surgical
intervention. All in all, it is clear that there is room
for further evaluation, because our study had a
limited number of patients presenting with
PSRCCR. It is suggested that there is a lot to gain
by conducting relevant multicenter studies in the
future.
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